Результаты поиска

Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study.

BACKGROUND: Autologous stem cell transplantation (ASCT) is a standard treatment for newly diagnosed multiple myeloma (MM). Achieving sufficient stem cell yield via effective mobilization promotes successful hematological reconstitution. However, clinical evidence regarding the comparative outcomes of pegfilgrastim (PEG) versus filgrastim (FIL) remains controversial, lacking regimen-specific comparisons. OBJECTIVE: To evaluate the efficacy, safety, efficiency, and costs of PEG versus FIL in MM patients, and compare the impact of cyclophosphamide-based chemo-mobilization on these outcomes. STU…

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

Quantitative modeling can guide drug development and regulatory decisions by providing insights into pharmacokinetics, pharmacodynamics, efficacy, and safety. Integrating models allows simulations that support dosing considerations. A simulation framework for belantamab mafodotin (B) in relapsed/refractory multiple myeloma was developed using data from monotherapy studies and combination studies with bortezomib/dexamethasone (BVd) and pomalidomide/dexamethasone (BPd). Individual changes from baseline in serum M-protein concentrations were modeled using a tumor growth inhibition model. Changes …

Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report.

BACKGROUND: Chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA CAR-T) has significantly improved outcomes in relapsed/refractory multiple myeloma (R/RMM), yet its spectrum of immune-related adverse events continues to be defined. Among these, cutaneous toxicities are not unusual, but frequently receive insufficient attention. Delayed-onset cutaneous reactions, in particular, may be underreported. CASE REPORT: We report a patient with R/RMM who achieved stringent complete response (sCR) following BCMA CAR-T therapy and developed delayed-onset cutaneous lesions o…

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Dynamic changes in myeloid-derived suppressor cells (MDSCs) during multiple myeloma (MM) treatment remain poorly understood. In this longitudinal observational study, circulating monocytic (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) were measured by flow cytometry in 99 newly diagnosed MM patients at diagnosis, post-induction, and Day 100 after autologous stem cell transplantation (ASCT). Primary analyses were restricted to the bortezomib-lenalidomide-dexamethasone (VRd)-treated cohort (n = 78) to avoid regimen-specific confounding. VRd, but not daratumumab-based regimens, significantly …

Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.

Deletion (13q)/monosomy 13 (del[13q]/-13) is common in multiple myeloma (MM), but its independent prognostic value remains unclear, particularly in patients treated with modern therapy and upfront autologous haematopoietic stem cell transplantation (autoHSCT). This study aimed to assess its impact on progression-free survival (PFS) and overall survival (OS), and to evaluate its prognostic impact in the context of established high-risk cytogenetic abnormalities (HRCA). We conducted a retrospective, single-centre study of MM patients undergoing autoHSCT between 2010 and 2021 with available fluor…

- Имитационная оценка соответствия режима дозировки многочисленным миеломным лекарствам, отражающим демографические и этнические различия.

Из-за трудностей, связанных с проведением клинических испытаний в небольших и неоднородных группах населения, часто не проводятся исследования, посвященные таким болезням сирот, как множественная миелома (ММ). Вместе с тем демографические и региональные различия между участниками испытаний и азиатскими группами населения могут влиять на воздействие наркотиков и принимаемые меры реагирования. В этом исследовании была проведена оценка потенциальных различий в воздействии наркотиков и реакции на них между многонациональными клиническими пробными группами населения (ТП) и корейскими пациентами (КП…

[Who refer patients with multiple myeloma to hematology-oncology: A retrospective study at Hôtel-Dieu de France].

INTRODUCTION: Multiple myeloma presents with a wide spectrum of symptoms that may initially direct patients to different medical specialties. This study aims to identify the specialties that most frequently refer newly diagnosed patients to hemato-oncology. METHODS: A retrospective study was conducted using the medical records of adult patients diagnosed with multiple myeloma at the Hôtel-Dieu de France University Hospital between 2013 and 2024. Collected data included the referring specialty, age, sex, isotypes, percentage of bone marrow plasma cells, prognostic factors, the Revised Internat…

Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma.

Alterations in the redox status and the DNA damage response (DDR) parameters are early, mechanistically interconnected drivers of carcinogenesis. Herein, we investigated whether such alterations, arising during the progression of Multiple Myeloma (MM), are systemically reflected in peripheral blood mononuclear cells (PBMCs). Redox status, expressed as the GSH/GSSG ratio, and DDR-related parameters, including baseline DNA damage, efficiency of key DNA repair pathways, namely nucleotide excision repair (NER) and double-strand break repair (DSB/R), as well as apoptotic sensitivity, were evaluated…

Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience.

INTRODUCTION: Assessment of measurable residual disease (MRD) in multiple myeloma (MM) often relies on repeated bone marrow evaluations, which are invasive, costly, and not universally accessible. Alternative monitoring approaches based on routinely available laboratory tests may provide clinically relevant prognostic information. OBJECTIVES: To evaluate whether longitudinal follow-up based exclusively on serologic monitoring can predict survival outcomes in a real-world cohort of patients with MM. METHODS: This retrospective single-center study included 88 consecutive patients diagnosed wit…

Активировать новый способ смерти клеток, чтобы убить ПИ-стойкую миелому и усилить иммуногенную смерть клеток.

Стойкость к протеиновым ингибиторам (ИП) и недостаточное использование иммунитета против опухоли по-прежнему являются основными препятствиями для эффективного лечения множественной миеломы (ММ). Здесь мы идентифицировали биоактивный естественный продукт авулиганна как перспективный в переводе агент, который сохраняет активность в клетках MM, устойчивых к PI, и поощряет иммунную реакцию против миломы. Anwulignan продемонстрировал мощную цитотоксичную активность против клеток MM и продемонстрировал мощный синергетический эффект с протеаозными ингибиторами как in vitro, так и in vivo. В моделях M…

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.

Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP-array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression-free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS (p = 0.0024) and PFS (p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21+ (p = 0.011) but…

A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens.

BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy, requiring sustained therapeutic management to mitigate disease recurrence. Ixazomib, a first-generation oral proteasome inhibitor, has exhibited substantial clinical efficacy and is widely employed in clinical practice. According to prescribing guidelines, ixazomib is typically administered at an initial dose of 4 mg weekly for 3 weeks, with dose reduction to 3 mg weekly in the event of adverse effects. Prior exposure-response analyses have confirmed that both 3 and 4 mg doses reside within the clinically effective range…

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy.

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy is highly active in relapsed/refractory multiple myeloma (RRMM), but manufacturing creates an obligatory waiting period between apheresis and infusion. Patients may deteriorate, progress or die during this window. Analyses that begin follow-up at infusion exclude these patients entirely and cannot describe the experience of all patients who enter the CAR-T pathway. AIM: To describe, in an intention-to-collect fashion, the outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy; to characterise the apher…

Длительный длинный межваловый теклистамб и талькетамаб дозируют без увеличения дозирования в ранее обработанной множественной миеломе.

Teclistamab (Tec) и Talquetamab (Tal) являются двуэлементными CD3 T-клеточными участниками, направленными против антигена B-клеток и G-белкового рецептора, класс C, группа 5, член D, соответственно, и изменил наше отношение к рецидиву/изъятию множественной миэломы (RRMM). Токсичные свойства на ранней стадии, такие, как синдром цитокина (CRS) и синдром нейротоксичности, связанный с иммунным действием клеток (ICANS), требуют использования предлежащих препаратов, прививки (SUD), а также тщательного мониторинга при запоздалых токсичных свойствах, таких, как гипогаммаглобулиномия, миэлосипация и, в

Совпадение в аннотации оригинала
Teclistamab (Tec) and talquetamab (Tal) are bispecific CD3 T-cell engagers targeting B-cell maturation antigen and G protein-coupled receptor, class C, group 5, member D, respectively, and have transformed how we treat relapsed/refractory multiple myeloma (RRMM). Early onset toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associa…

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up.

BACKGROUND/AIM: Autologous stem cell transplantation (ASCT) is the standard strategy after induction therapy for newly diagnosed transplant-eligible multiple myeloma. High-dose melphalan (HDM) conditioning has been the recommended treatment regimen for a long time. No other conditioning regimen has been proven safer and more effective. Because bortezomib has a synergistic effect with melphalan, bortezomib with HDM (Bor-HDM) as a conditioning regimen has shown favorable outcomes, improved complete response rates after ASCT, and no prolonged hematological toxicities. However, few studies have re…

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.

Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planne…

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

PURPOSE: Survival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was to investigate the consistency of association of co-occurrence of high-risk cytogenetic abnormalities (HRCAs) with prognosis in patients with newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM), and across a range of treatment modalities. METHODS: A systematic review of randomized controlled trials of MM that reported testing for HRCA between January 1, 2000, and Decem…

PMEPA1 Binds NEDD4L to Inhibit the Malignant Progression of Multiple Myeloma by Inactivating Wnt/β-Catenin Signaling.

Multiple myeloma (MM) is an incurable hematological malignancy with increasing prevalence. Prostate transmembrane androgen inducible protein 1 (PMEPA1) is positively associated with overall survival in MM patients, but the exact functions and mechanisms of PMEPA1 in MM have yet to be elucidated. PMEPA1 and neural precursor cell-expressed developmentally downregulated gene 4L (NEDD4L) levels in MM cells were examined. In RPMI-8226 cells with PMEPA1 overexpression or/and NEDD4L knockdown, cell proliferation, cycle distribution and apoptosis were evaluated with the application of CCK-8, EDU stain…

Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma.

BACKGROUND: Standard-of-care treatment for patients with multiple myeloma (MM) typically includes frontline lenalidomide until disease progression, making lenalidomide-refractoriness a challenge in relapsed/refractory MM (RRMM). Lenalidomide-sparing triplet therapies, daratumumab, pomalidomide, and dexamethasone (DPd) and pomalidomide, bortezomib, and dexamethasone (PVd), demonstrated efficacy in lenalidomide-exposed patients in the APOLLO and OPTIMISMM trials, respectively. Without head-to-head trial data, we assessed the comparative effectiveness of DPd versus PVd via matching-adjusted indir…